IMMUNABS
3.8.2022 16:02:08 CEST | Business Wire | Press release
ImmunAbs Inc. (www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ , patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Announced its Q1’2026 Results Presenting Accelerated Growth in the Specialty Ingredients & Solutions Activity11.5.2026 12:03:00 CEST | Press release
SIS revenues (Specialty Ingredients & Solutions) grew 64% in Q1 into 19.7 million dollars (growth of 27% on a LFL1 basis).Group revenue for the quarter grew 4% into 91.5 million dollars.Adjusted EBITDA2 for the SIS activity grew 95% into 3.6 million dollars, reflecting an adjusted EBITDA margin of 18%.Adjusted net profit grew 19% into 3.9 million dollars.Cash flow from operating activities surged into 15.0 million dollars. Tsahi Barak, Chairman of the Board and CEO of the Company, stated: “We are pleased to report a strong quarter during which we continued to successfully implement the company’s business strategy, which emphasizes, among other things, significant and profitable growth in the Specialty Ingredients & Solutions activity and the expansion of Solos’ infrastructure, our dealcoholization division. We believe that the positive momentum in this activity will continue throughout the year, as we continuously work to leverage the many opportunities across the various markets. The
Corpay Partners With BVNK To Add Stablecoin Wallets for Global Customers11.5.2026 12:00:00 CEST | Press release
Corpay, Inc. (NYSE: CPAY), the leading corporate payments company, today announced that it is partnering with stablecoin infrastructure platform BVNK to provide stablecoin wallets and settlement capabilities to its global customer base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511711546/en/ The integration will enable Corpay’s customers to see a stablecoin balance alongside their fiat balances, and provide customers with embedded stablecoin wallets for sending, receiving, storing, and converting stablecoins within its platform. Customers will now have access to the always-on payment rails that operate beyond the limits of traditional banking hours and systems. Corpay will also integrate stablecoin rails in its treasury operations, reducing reliance on pre-funded accounts, improving capital efficiency, and improving the movement of funds across its global footprint outside of its own proprietary network. Corpay serve
Ant International Highlights Democratising AI and Strengthening Trust in 2025 Sustainability Report11.5.2026 11:17:00 CEST | Press release
Company now provides global account services to 1.6 mn SMEs, and credit access to over 30 mn underserved With the inclusion principle integrated into main innovation projects, Ant International now links 2 bn user accounts with 150 mn merchants through multi-layered partnerships, provides global account services to 1.6 mn SMEs, and helps over 30 mn underserved businesses and individuals access quality credit. As its global payment, global account and embedded finance services expand rapidly, it is accelerating investments in compliance capabilities and advanced security technologies to tackle evolving regulatory and risk environments. From basketball courts in New York to marine protection in Java Indonesia, we build extensive partnerships to protect the environment and empower local communities. Ant International, a leading global digital payment, digitisation and financial technology provider, today published its 2025 Sustainability Report, the 2nd since the Company began independent
Dryad Launches Gen-4-Pro Silvanet Wildfire Sensor, Setting New Standard in Ultra-Early Fire Detection11.5.2026 11:09:00 CEST | Press release
Next-generation technology delivers unmatched detection speed, accuracy, and connectivity for global wildfire prevention Dryad Networks, a global leader in ultra-early wildfire detection technology, today announced the launch and immediate availability of the Gen-4-Pro Silvanet Wildfire Sensor, the fourth generation of its industry-leading Silvanet solution. The new Gen-4-Pro sensor introduces significant advancements in detection capability, energy autonomy, and connectivity—further strengthening Dryad’s mission to protect forests, infrastructure, and communities from the growing threat of wildfires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260510819235/en/ Silvanet Wildfire Sensor Gen4Pro enables ultra-early wildfire detection and environmental data monitoring. The Silvanet suite is a comprehensive wildfire detection system combining solar-powered gas sensors, a large-scale wireless IoT network, and cloud-based analy
Macnica ATD Europe Acquires Indesmatech to Deepen Engineering Presence Across Northern Europe11.5.2026 11:00:00 CEST | Press release
Strategic acquisition strengthens Macnica ATD Europe’s early-stage engagement, engineering support and coverage across Scandinavia and Northern Europe. Macnica ATD Europe today announced the acquisition of Indesmatech, a pan-European technology and advisory company specializing in advanced semiconductor representation, design-in support and consulting, as well as point click buying services. The acquisition is a strategic move by Macnica ATD Europe to strengthen its commercial and engineering presence across Scandinavia and Northern Europe, adding established regional relationships, in-house engineering capabilities and a proven ecosystem-led approach in line with its already strong presence in the region. It’s business focus areas include IoT, communications and power, embedded computing, memory and ASIC, and audio and sensing applications. This complements Macnica ATD Europe’s existing portfolio and reinforces its ability to support customers across a wide range of technology-driven
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom